Literature Highlights - August 2023
AURORA 2, Voclosporin, Lupus Nephritis, BLISS-LN, Belimumab
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
AURORA 2, Voclosporin, Lupus Nephritis, BLISS-LN, Belimumab
Lancet. 2023 doi: 10.1016/S0140-6736(22)02546-6 Epub ahead of print
Negative results of SLE-BRAVE-II trial show that evidence for the efficacy of baricitinib in SLE is inconclusive.
Lancet. 2023 doi: 10.1016/S0140-6736(22)02607-1 Epub ahead of print
Primary endpoint in SLE-BRAVE-I study was met for the 4 mg baricitinib group, however, key secondary endpoints were not.
Arthritis Res Ther 2022;24(1):112 doi: 10.1186/s13075-022-02794-x
Evaluation of serological activity, including antibodies against double-stranded DNA (anti-dsDNA), suggests that baricitinib may influence B cell activity in systemic lupus erythematosus (SLE).
Lancet 2018;392:222–31
This international Phase 2 study aimed to assess the efficacy and safety of baricitinib, an oral JAK-1 and -2 inhibitor, in patients with SLE who were not adequately controlled despite standard background therapy.